The PVRI 7th Annual Drug Discovery & Development Symposium for Pulmonary Hypertension, originally scheduled to take place in Boston, USA, was presented digitally following the COVID-19 pandemic on 29 June 2020.
Our scientific organisers set an exciting programme of featured presentations, which were released over a five-day period from 24-28 June 2020, and were culminated by a live webinar on 29 June.
Digital format proves its success
Nearly 220 participants joined the session and were able to ask and upvote questions, participate in polls and download slides.
Professor Paul Hassoun, Johns Hopkins University School of Medicine, USA, Professor Allan Lawrie, University of Sheffield, UK, and Dr Anna Hemnes, Vanderbilt University Medical Center, USA, moderated the following talks:
- Clinical development of inhaled GB002 for the treatment of pulmonary arterial hypertension, sponsored by Gossamer Bio.
Presented by Professor Ardeschir Ghofrani, Justus-Liebig-University Giessen, Germany, whose presentation received an average score of 9/10
- A study of sotatercept for the treatment of pulmonary arterial hypertension (PULSAR, NCT03496207), sponsored by Acceleron
Presented by Dr David Badesch, University of Colorado, USA, whose presentation received a score of 9/10
- Pharmacogenomics and placebo response in a randomised clinical trial
Presented by Dr Kathryn Hall, Brigham and Women's Hospital, Harvard Medical School, USA, whose presentation received a score of 9/10
The delivery of the new format of the virtual meeting received an overall score of 9/10.